RESEARCH MONOGRAPH · KDC-MN-192

Milnacipran

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

70/100

The SNRI nobody in North America talks about. Fibromyalgia signal is real, depression signal is mediocre

Milnacipran is interesting because it's basically a balanced SNRI with a different binding ratio than venlafaxine or duloxetine. The norepinephrine-to-serotonin reuptake inhibition ratio sits closer to 1:1 (some sources put it slightly NE-favored), which is unusual in the class and probably explains why the fibromyalgia data is stronger than the depression data. In Japan and Europe it's been used as an antidepressant for decades. In the US it got an FDA approval for fibromyalgia only, which is one of those regulatory quirks that obscures the actual pharmacology.

The fibromyalgia trials are where the signal is genuinely interesting. Pain endpoints, fatigue, and physical function improved in multiple placebo-controlled studies, and the effect size is small but consistent. Mechanism-wise this fits the descending pain inhibition story: noradrenergic tone in the spinal dorsal horn modulates central sensitization, and milnacipran's relatively NE-heavy profile makes it well-suited to that pathway. Duloxetine works similarly but with stronger serotonergic action that may explain its different side effect profile.

What we like is that the side effect pattern is actually different from venlafaxine. Less GI nausea, more urinary hesitancy (the alpha-adrenergic effect at the bladder), more sweating and tachycardia at higher doses. Sexual dysfunction is present but milder than SSRIs in the comparative data. Discontinuation is reportedly easier than venlafaxine, partly because the half-life is around 8 hours.

Where it falls short is depression as a primary indication. The MDD evidence is roughly equivalent to standard SSRIs but no better, and the side effect tradeoff doesn't favor it. As an antidepressant in 2026 it's basically obsolete except for specific patient profiles. As a research tool for studying balanced NE/5-HT pharmacology or pain pathways, it's underused and underappreciated.

Sourcing is fine for research material, milnacipran has been off-patent in most jurisdictions for years and reference standards are widely available. The (1S,2R) levomilnacipran enantiomer is the pure-SNRI version that's still patented in the US, which is its own story (see KDC-MN-213). For most preclinical work the racemate is appropriate and considerably cheaper.

Evidence: 70
Mechanism: 78
Reliability: 65
Safety: 78
Sourcing: 78
Value: 70
Signal: 60
Staying power: 60

Plain-language summary Intrigue 60 / 100

Milnacipran, sold as Savella in the US (Ixel in Europe), is an SNRI primarily used for fibromyalgia. The European indication is depression. The (1S,2R)-enantiomer (levomilnacipran, Fetzima) is sold separately as a depression-focused agent. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Serotonin-norepinephrine reuptake inhibitor

An SNRI marketed in Europe and Japan for depression and FDA-approved for fibromyalgia, with balanced SERT/NET inhibition.

Abstract

Milnacipran (Savella, Ixel; CAS 92623-85-3; molecular formula C15H22N2O; molecular weight 246.35) is a serotonin-norepinephrine reuptake inhibitor (SNRI) marketed in Europe, Japan, and Australia for major depressive disorder and FDA-approved in 2009 (Savella) for fibromyalgia. The compound has more balanced SERT and NET inhibition than venlafaxine or duloxetine (which are SERT-biased), with NET inhibition more prominent at lower doses. Reported research dose ranges in the literature are described in the source publications.

Mechanism of action

Balanced SNRI with NET inhibition more prominent at lower doses.

Reported research dose ranges

Reported research dose ranges in the literature.

References

Mendlewicz J. Pharmacologic profile and efficacy of milnacipran. Eur Neuropsychopharmacol 1995.

Read the full monograph

Available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-192

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Milnacipran

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs